###begin article-title 0
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 8 13 8 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 28 30 28 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 239 243 239 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 441 446 441 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 570 579 570 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
###xml 836 841 <span type="species:ncbi:9606">human</span>
Recent studies have demonstrated a direct involvement of B7-H1, PD-1 and FOXP3 molecules in the immune escape of cancer. B7-H1 is an inhibitory molecule that binds to PD-1 on T lymphocytes, while FOXP3 is a marker for regulatory T cells (Tregs). We have previously demonstrated the association of B7-H1-expressing T infiltrating lymphocytes (TIL) with high-risk breast cancer patients while other studies reported the involvement of FOXP3+ Tregs as a bad prognostic factor in breast tumors. Although the co-existence between the two types of cells has been demonstrated in vitro and animal models, their relative infiltration and correlation with the clinicopathological parameters of cancer patients have not been well studied. Therefore, we investigated TIL-expressing the B7-H1, PD-1, and FOXP3 molecules, in the microenvironment of human breast tumors and their possible association with the progression of the disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Using immunohistochemistry, tumor sections from 62 breast cancer patients were co-stained for B7-H1, PD-1 and FOXP3 molecules and their expression was statistically correlated with factors known to be involved in the progression of the disease.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 23 25 23 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 51 56 51 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 128 130 128 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 264 266 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 267 271 267 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 278 280 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 357 359 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 467 469 467 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
A co-existence of B7-H1+ T lymphocytes and FOXP3+ Tregs was evidenced by the highly significant correlation of these molecules (P < .0001) and their expression by different T lymphocyte subsets was clearly demonstrated. Interestingly, concomitant presence of FOXP3+ Tregs, B7-H1+ and PD-1+ TIL synergistically correlated with high histological grade (III) (P < .001), estrogen receptor negative status (P = .017), and the presence of severe lymphocytic infiltration (P = .022).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 211 216 211 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Accumulation of TIL-expressing such inhibitory molecules may deteriorate the immunity of high-risk breast cancer patients and this should encourage vigorous combinatorial immunotherapeutic approaches targeting Tregs and B7-H1/PD-1 molecules.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 767 769 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 671 678 <span type="species:ncbi:9606">patient</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
###xml 990 998 <span type="species:ncbi:9606">patients</span>
It is widely believed that dysfunction in the immune system of cancer patients allows the tumor cells to escape a process termed immunosurveillance [1-3]. A T lymphocytes inhibitory molecule named B7-H1 (also called PD-L1) expressed by antigen presenting cells has been shown to induce T lymphocyte anergy and/or apoptosis after ligation to its T lymphocytes receptor PD-1 [4-7]. B7-H1 has been shown to be directly involved in the protection of cancer cells from activated T lymphocytes [8]. Indeed, the expression of this molecule and its receptor has been described in several malignancies [9-17] where a strong link between its expression by the cancer cells and the patient clinicopathological status has been demonstrated in some of these malignancies [9,11,13,16]. We have shown previously that B7-H1 (PD-L1) is expressed in the tumor tissues of 50% of breast cancer patients and its expression was significantly associated with some important prognostic factors linked to high-risk patients [18].
###end p 11
###begin p 12
###xml 21 25 21 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 185 190 185 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 391 396 391 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 556 561 556 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 646 651 646 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 791 796 791 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 869 871 869 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 956 961 956 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 484 489 <span type="species:ncbi:9606">human</span>
###xml 626 631 <span type="species:ncbi:9606">human</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
###xml 988 996 <span type="species:ncbi:9606">patients</span>
Regulatory T cells (Tregs) are a subset of T lymphocytes that regulate the immune response by suppressing the proliferation and cytokines production of effector T lymphocytes [19,20]. Tregs are thus important for protecting our body by suppressing auto-reactive T lymphocytes. FOXP3, a forkhead/winged helix transcription factor was found to be essential for the development and control of Tregs [21,22]. It has been used recently as a biomarker and a prognostic factor for malignant human tumor as reviewed in [23]. A direct link between the presence of Tregs and progression of ovarian carcinoma has been demonstrated where human tumor FOXP3+ Tregs were found to suppress tumor specific immunity and contribute to reduced survival of these patients [24]. In breast cancer, an increase in Tregs population both in peripheral blood and tumor tissues was also reported [25] and a recent study demonstrated a significant intratumoral infiltration of FOXP3+ Tregs in high-risk breast cancer patients and those at risk of late relapse [26].
###end p 12
###begin p 13
###xml 102 106 102 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 138 140 138 140 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 141 146 141 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 190 192 190 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 237 242 237 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 394 396 394 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 397 402 397 402 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 540 545 540 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 655 660 655 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 784 788 784 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 906 911 906 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1056 1061 1056 1061 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 957 965 <span type="species:ncbi:9606">patients</span>
###xml 1112 1120 <span type="species:ncbi:9606">patients</span>
Compelling evidences indicate a key role for the involvement of B7-H1 molecule in the development of Tregs. Induction of adaptive CD4+CD25+ Tregs which develop in the periphery from CD4+CD25- naive T lymphocytes (in contrast to natural Tregs formed in the thymus) could not be formed in mice which are B7 -/- [27]. In addition, mice vascular endothelial cells were able to induce CD4+CD25+FOXP3+ Tregs only in the presence of B7-H1 [28]. Another study has demonstrated the involvement of B7-H1 as an essential element for the induction of Tregs after intra-tracheal delivery of an alloantigen [29]. Furthermore, B7-H1 was found to affect the function of Tregs in which its blockade decreased the inhibitory effect of such cells [30] and blockade of B7-H1/PD-1 interactions abrogated Tregs-mediated immunoregulation [31]. Although these studies have demonstrated the interaction between B7-H1 molecule and Tregs in animal models their co-existence in cancer patients was not evaluated. This is the first study to investigate the correlation between FOXP3+ Tregs and TIL-expressing B7-H1 and PD-1 in breast cancer patients. We have shown that their co-infiltration is strongly associated with high-risk prognostic factors and those T lymphocytes expressing FOXP3, B7-H1 and PD-1 molecules are of different T lymphocytes subsets.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples collection
###end title 15
###begin p 16
###xml 73 81 <span type="species:ncbi:9606">patients</span>
This study was conducted in accordance with Helsinki Declaration and all patients signed a consent form approved by the Research Ethics Committee of King Faisal Specialist Hospital and Research Center (KFSH&RC). The study was approved by the Research Advisory Council (RAC) of KFSH&RC (RAC# 2030 034).
###end p 16
###begin p 17
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 766 768 766 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 447 452 <span type="species:ncbi:9606">women</span>
Breast cancer specimens were collected from primary tumors of 68 patients including the 44 patients reported in our previous study [18] (median age 44 years) who were seeking treatments and had to undergo surgery (breast conservative surgery or total mastectomy) at KFSH&RC from 2003 to 2006. From the selected patients, 6 patients were removed from the study as they had no detectable TIL. Normal breast tissues were also obtained from 2 healthy women undergoing a plastic surgery and designated as BP. Upon excision of tissues by a surgeon, an anatomical pathologist obtained sample of the tumor tissue, denoted T, and an adjacent normal breast tissue from the same breast having the tumor, denoted N. Tissues from both T and N were processed as described before [18]. Briefly, they were fixed in formalin and embedded in paraffin for routine histopathological analysis while other piece was snap frozen in liquid nitrogen, preserved at -80degreesC and sectioned using a cryostat.
###end p 17
###begin title 18
Immunohistochemistry
###end title 18
###begin p 19
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Routine formalin-fixed, paraffin-embedded hospital tests were evaluated by immunohistochemistry for Her/2neu, Estrogen receptor, and progesterone receptor status as described before [18] while immunohistochemistry staining of frozen tissue sections were carried out as follows:
###end p 19
###begin title 20
(a) Single staining
###end title 20
###begin p 21
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 488 492 <span type="species:ncbi:9925">goat</span>
###xml 766 777 <span type="species:ncbi:3704">horseradish</span>
B7-H1 and PD-1 detection were carried out as described previously on fresh cryogenic sections with slight modifications [18,32] in which a very brief fixation in 2% paraformaldehyde (Fisher scientific) in PBS at RT (4 minutes for B7-H1 and 10 minutes for PD-1) was initially applied to improve the morphology of section. Briefly, sections were incubated for 15 minutes in 0.3% hydrogen peroxide solution and 0.1% sodium azide (Sigma, Saint Louis, MO, USA). Sections were blocked with 10% goat serum (DAKO, Denmark) for 30 minutes followed by B7-H1 antibody (MIH1 clone, ebioscience, San Diego, CA, USA) or PD-1 antibody (J116 clone, ebioscience,) diluted at 1:50 overnight. After washing, sections were stained for 30 minutes at RT, with Labeled Polymer (EnVision+) horseradish peroxidase (HRP) detection kit (DAKO). Colors were developed using DAB (Novocastra, Newcastle upon Tyne, UK) or AEC (Sigma) and sections were counterstained with instant hematoxylin (Shandon, Pittsburgh, PA, USA).
###end p 21
###begin title 22
(b) Double staining
###end title 22
###begin p 23
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 99 103 <span type="species:ncbi:9925">goat</span>
###xml 307 312 <span type="species:ncbi:10090">mouse</span>
###xml 371 376 <span type="species:ncbi:10090">mouse</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
###xml 516 522 <span type="species:ncbi:9986">rabbit</span>
###xml 559 565 <span type="species:ncbi:9986">rabbit</span>
###xml 632 637 <span type="species:ncbi:9606">human</span>
###xml 810 815 <span type="species:ncbi:9823">swine</span>
###xml 821 827 <span type="species:ncbi:9986">rabbit</span>
###xml 1201 1207 <span type="species:ncbi:9986">rabbit</span>
###xml 1268 1273 <span type="species:ncbi:10090">mouse</span>
###xml 1660 1665 <span type="species:ncbi:10090">mouse</span>
###xml 1762 1766 <span type="species:ncbi:9925">goat</span>
###xml 1772 1777 <span type="species:ncbi:10090">mouse</span>
Sections were washed in PBS, incubated with paraformaldehyde for 4 minutes and blocked in H2O2 and goat serum as described above. The primary and secondary antibodies were added as follows: For CD3/FOXP3, CD8/FOXP3, CD8/PD-1 or CD8/B7-H1 double staining the 2 primary antibodies from two different species, mouse anti-FOXP3 (236A/E7 clone, ebioscience) diluted at 1:100, mouse anti-B7-H1 (clone MIH1, ebioscience) diluted at 1:25 or mouse anti-PD-1 antibody (J116 clone, ebioscience) diluted at 1:50 were mixed with rabbit anti-CD3 (Dako) at 1:50 dilution or rabbit anti-CD8 (Abcam, Cambridge, UK) at 1:75 dilution, together in 10% human AB serum (Cambrex) and incubated for 2 h at RT or overnight at 4degreesC. Sections were washed 3 times in PBS and incubated for 30 minutes at RT with a secondary antibody: swine anti-rabbit AP (Dako) diluted at 1:50 in a ready-to-use polymer (Envision+, Dako) linked to HRP. After washing 3 times with PBS, substrates were added starting with fuschin red (Dako) followed by DAB (Novocastra). Slides were counterstained with instant hematoxylin (Shandon). FOXP3 and B7-H1 double staining were carried out as described above except the primary antibodies used were rabbit anti-FOXP3 (polyclonal, Abcam) at 1:500 dilution mixed with mouse anti-B7-H1 (clone MIH1, ebioscience) at 1:25 dilution and overnight incubation at 4degreesC. FOXP3 and PD-1 double staining were started with a single staining of PD-1 as before, however after color development with DAB, sections were boiled for 3 minutes in an antigen retrieval citrate solution (pH = 6.0) to remove previously attached antibodies. FOXP3 antigen was then stained with mouse anti-FOXP3 antibody (236A/E7 clone, ebioscience) diluted at 1:100 for 2 hours at RT followed by goat anti-mouse IgG1 AP (Southern Biotech, Birmingham, Alabama, USA) for 30 minutes at RT. The color for FOXP3 staining was developed with Fuschin Red (Dako) and sections were counterstained with instant hematoxylin (Shandon).
###end p 23
###begin title 24
Interpretation of stained tumor sections
###end title 24
###begin p 25
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 109 111 109 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 258 259 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 263 265 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 328 330 328 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 359 361 359 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 428 433 428 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
The B7-H1 and PD-1 staining were scored by an anatomical pathologist (AT) as described previously [18]. FOXP3+ T lymphocytes were scored in 5-10% increments as a percentage of total CD3+ staining cells in several high magnification fields. Intratumoral FOXP3+/CD3+ cells were only considered and counted while intrastromal FOXP3+ cells were disregarded. FOXP3+ cells with moderate or high intensity (++ or +++) were considered Tregs while weak staining (+) were ignored. Due to the co localization of the CD3 and PD-1 molecules in the T lymphocyte membranes, double staining of PD-1 or B7-H1 and CD3 were assumed based on single-staining of sequential slides. The cut off point for positive and negative for FOXP3, B7-H1 and PD-1 was 5% (5% of total CD3+ T-lymphocytes).
###end p 25
###begin title 26
Statistical Analysis
###end title 26
###begin p 27
###xml 104 106 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 107 112 107 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 219 225 <span type="species:ncbi:76720">fisher</span>
Statistical analyses were used to determine the association between the B7-H1 expression in TIL or FOXP3+ Tregs infiltration and the patients' clinico-pathological parameters. Nominal parameters were analyzed using the fisher exact test. Comparisons of the independent variables with the dependent variable were performed using a simple logistic regression analysis. Significance was defined as the probability of a type one error of < 5%, and 95% confidence intervals were included. The software package SAS was used for these analyses.
###end p 27
###begin title 28
Results
###end title 28
###begin title 29
###xml 16 20 16 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
Frequencies of Tregs, B7-H1+ and PD-1+ T lymphocytes in normal and breast cancer tissues
###end title 29
###begin p 30
###xml 42 46 42 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 382 384 382 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 385 390 385 390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 422 424 422 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 603 605 603 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 738 743 738 743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 797 799 797 799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 810 815 810 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1105 1107 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1284 1286 1284 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F</xref>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
###xml 1223 1231 <span type="species:ncbi:9606">patients</span>
In order to determine the frequencies of Tregs, B7-H1 and PD-1 expressing-T lymphocytes in normal breast tissues we stained sections obtained from breast patients undergoing plastic surgery (BP) as well as normal breast tissues adjacent to breast cancer tumors (N) for the expression of FOXP3, B7-H1 and PD-1 molecules. There were a few T lymphocytes in both N and BP in which FOXP3+ Tregs represented <5% of the total CD3+ TIL (Figure 1A). Similarly, T lymphocytes in normal tissues were negative for B7-H1 (Figure 1B). However, PD-1+ T lymphocytes were abundant in normal tissues with up to 30% of CD3+ cells co-expressing the PD-1 molecule (Figure 1C). In contrast to normal breast tissues, 56% of breast cancer patients had a higher Tregs frequency in their tumor tissues in which 5-50% of CD3+ TILs were Tregs (Figure 1D). Similarly, B7-H1 was expressed in TILs of 54% of breast cancer patients' tumor tissues in which 5-80% of TILs express this molecule. B7-H1 expression was not restricted to T lymphocytes as 30% of breast cancer patients showed also B7-H1 expression in their tumor cells (Figure 1E). This result was also described in our previous study [18]. The PD-1 molecule was expressed in TILs in 60% of the patients in which 5-70% of TIL express this molecule (Figure 1F). The expression pattern of the PD-1 molecule was membranous and restricted to T lymphocytes only.
###end p 30
###begin p 31
###xml 40 45 40 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemical staining of FOXP3+ T<sub>regs </sub>B7-H1 +and PD-1+ in T lymphocytes of breast tissues</bold>
Immunohistochemical staining of FOXP3+ Tregs B7-H1 +and PD-1+ in T lymphocytes of breast tissues. Representative micrographs at x 530 magnification of (A&D) CD3/FOXP3 double staining (red color, membranous for CD3 and brown nuclear color for FOXP3 expression). (B&E) B7-H1 single staining (brown color, membranous/cytoplasmic expression). (C&F) PD-1 single staining (brown color, membranous expression). Upper panel (A-C) is sections for normal breast duct and lower panel (D-F) is sections for infiltrating ductal carcinoma of the breast.
###end p 31
###begin p 32
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 156 161 156 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 250 255 250 255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 305 307 305 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Both intratumoral and intrastromal FOXP3+CD3+ cells were present in the patients tissues (Figure 2A) and the expression level of FOXP3 in the intratumoral Tregs ranged from weak to intense (Figure 2B). Interestingly, most of FOXP3 intensely stained Tregs were found in close proximity to tumor cells. PD-1+ T lymphocytes were found both intrastromal and intratumoral, where they commonly seen in clumps, or as clumps/single cells respectively.
###end p 32
###begin p 33
###xml 75 80 75 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 0 104 0 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemical staining showing intratumoral and intrastromal FOXP3+ T<sub>regs </sub>in breast cancer tissues</bold>
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/</sup>
###xml 342 344 342 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 345 349 345 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">reg </sub>
###xml 386 387 386 387 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 393 395 393 395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 423 425 423 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Immunohistochemical staining showing intratumoral and intrastromal FOXP3+ Tregs in breast cancer tissues. Representative micrographs at x 530 magnification of CD3+ (red color membranous expression) and FOXP3+ (brown color nuclear expression) TIL of (A) intrastromal (left) and intratumoral (right) sections. Solid arrow indicates a CD3+/FOXP3+ Treg cell and dashed arrow indicates a CD3+/FOXP3- cell. (B) Intratumoral FOXP3+ TIL with different staining intensity (Intense, Medium, and weak). Cells were counterstained with hematoxylin.
###end p 33
###begin title 34
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Correlation of FOXP3, B7-H1 and PD-1 expression in TIL with clinicopathological parameters of patients
###end title 34
###begin p 35
###xml 60 65 60 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 178 180 178 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 213 215 213 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 259 261 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 306 308 306 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 338 343 338 343 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 576 581 576 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 664 669 664 669 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 670 672 670 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Breast cancer tissues infiltrated with intratumoral FOXP3+ Tregs were found to be significantly associated with patients who had bad prognostic factors such as large tumor size (P = .029), histological grade III (P < .001), estrogen receptor negative status (P = .010) and severe lymphocytic infiltration (P = .051). Intratumoral FOXP3+ Tregs were found also to be associated with progesterone receptor negative status and lymph node metastasis although they did not reach statistical significance (Table 1). The correlation of the expression B7-H1 in tumor cells and FOXP3+ Tregs was also studied. There was a correlation between B7-H1 in tumor cells and FOXP3+ Tregs (P < .019) (Table 1).
###end p 35
###begin p 36
###xml 20 22 20 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 23 27 23 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 34 36 34 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Correlation of FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL with the clinicopathological parameters of 62 breast cancer patients
###end p 36
###begin p 37
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Abbreviations</bold>
###xml 71 87 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9827;</sup>
###xml 145 146 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9670;</sup>
###xml 182 183 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9671;</sup>
###xml 220 222 205 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Abbreviations: (+ and -) are number of positive and negative patients, club suit symbolNumbers between brackets are the percentages of patients, ◆Two samples had unknown LN+ status, ◇Two samples had unknown PD-1 status *P values in bold represent a significant data.
###end p 37
###begin p 38
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 556 558 556 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 602 604 602 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 649 651 649 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 743 745 743 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 760 761 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 838 840 838 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1222 1226 1222 1226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 1318 1320 1318 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1364 1366 1364 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1417 1419 1417 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1434 1435 1434 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1511 1513 1511 1513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1528 1529 1528 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 1179 1187 <span type="species:ncbi:9606">patients</span>
###xml 1275 1283 <span type="species:ncbi:9606">patients</span>
We have reported previously on the expression of B7-H1 in 50% of 44 breast cancer patients; and found its expression in TIL to be significantly associated with large tumor size, high histological grade III, Her2/neu positive status and severe lymphocytic infiltration [18]. We further examined the B7-H1 expression in TIL of 62 breast cancer patients and correlated its expression with the same prognostic factors. Interestingly, very similar correlation was recorded for B7-H1+ TIL, and this was significantly associated with high histological grade III (P = .002), estrogen receptor negative status (P = .029), and sever lymphocytic infiltration (P = .017). There was also a correlation with large tumor size with a borderline significance (P = .072) (Table 1). There was also a correlation between B7-H1 in tumor cells and B7-H1+ TIL (P < .002) (Table 1). Although PD-1 molecule was also expressed by T lymphocytes infiltrating normal breast tissues lacking B7-H1, its presence in tumor tissues is considered essential for the inhibitory effect of B7-H1 molecule which is abundant in the tumor tissues. Therefore, we tested whether PD-1 is concomitantly expressed in the same patients along with B7-H1+ TIL and FOXP3+ Tregs. We have found that PD-1+ TILs were abundant in patients with high histological grade III (P = .001), estrogen receptor negative status (P = .001) and progesterone receptor negative status (P < .001) (Table 1). There was also a correlation between B7-H1 in tumor cells and PD-1+ TIL (P < .002) (Table 1).
###end p 38
###begin p 39
###xml 49 54 49 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 216 221 216 221 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 359 364 359 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 365 367 365 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 446 448 446 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 460 462 460 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 539 544 539 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 585 587 585 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
We have found that B7-H1+, PD-1+ TIL and FOXP3+ Tregs were significantly associated with similar bad prognostic factors. Therefore, we further investigated the correlation between B7-H1+ TIL or PD-1+ TIL and FOXP3+ Tregs infiltration in breast tumors. There was a highly significant correlation between the expression of B7-H1 in TIL and intratumoral FOXP3+ Tregs (P < .0001) as shown by ANOVA test (Figure 3A) and by linear regression analysis (P < .004 and R2 = 0.3) (Figure 3B). There was also a significant correlation between FOXP3+ Tregs infiltration and PD-1 expression in TIL (P = .007) as shown by ANOVA (Figure 3C).
###end p 39
###begin p 40
###xml 29 33 29 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 54 56 54 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlations between FOXP3+ T<sub>regs</sub>, B7-H1<sup>+ </sup>TIL and PD-1<sup>+ </sup>TIL</bold>
###xml 94 96 94 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 97 102 97 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 142 144 142 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 234 236 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 237 242 237 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 324 326 324 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 407 409 407 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 410 415 410 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 437 439 437 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 545 547 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 548 553 548 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 635 637 635 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
Correlations between FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL. (A) statistical analysis of FOXP3+ Tregs infiltration in tumor tissues with B7-H1+ TIL, as analyzed with ANOVA of three groups of breast cancer patients with different FOXP3+ Tregs infiltration (Low = 0 to 4%, Medium = 5 to 14% and High 15% and above of total CD3+ TIL), (B) their linear correlation analysis and (C) statistical analysis of FOXP3+ Tregs infiltration with PD-1+ TIL in breast cancer as analyzed with ANOVA of three groups of breast cancer patients with different FOXP3+ Tregs infiltration (Low = 0 to 4%, Medium = 5 to 14% and High 15% and above of total CD3+ TIL).
###end p 40
###begin title 41
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Correlation of combined FOXP3, and B7-H1 expression in TIL with clinicopathological parameters of patients
###end title 41
###begin p 42
###xml 217 222 217 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
We next tested whether a combination of FOXP3 and B7-H1 molecules will have a synergistic effect on the correlation with the patients' clinicopathological parameters. We used a combination of the two factors; FOXP3+ Tregs and B7-H1 expression in TIL in the presence of PD-1 expression (only patients with B7-H1-expressing TIL were considered positive when PD-1+ TIL were present in the same tissue). The combined molecules maintained a significant correlation with the same prognostic factors (Table 2).
###end p 42
###begin p 43
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Correlation between combined FOXP3+ T-reg and B7-H1 with the clinicopathological parameters of 62 breast cancer patients
###end p 43
###begin p 44
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Abbreviations</bold>
###xml 71 87 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9827;</sup>
###xml 145 146 130 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#9670;</sup>
###xml 182 184 167 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Abbreviations: (+ and -) are number of positive and negative patients, club suit symbolNumbers between brackets are the percentages of patients, ◆Two sample had unknown LN+ status, *P values in bold represent a significant data.
###end p 44
###begin title 45
Expression of FOXP3, B7-H1 and PD-1 molecules by different subsets of TIL
###end title 45
###begin p 46
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 164 168 164 168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 194 196 194 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 446 448 446 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 462 464 462 464 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 489 491 489 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 492 497 492 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 575 577 575 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 613 615 613 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 616 620 616 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 623 628 623 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 707 709 707 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 840 842 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1070 1075 1070 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1104 1106 1104 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1146 1148 1146 1148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1222 1224 1222 1224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1255 1257 1255 1257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1299 1301 1299 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1337 1339 1337 1339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1361 1363 1361 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 1447 1449 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
We next asked whether FOXP3, PD-1 and B7-H1 molecules are expressed by different T lymphocyte subsets. Double-staining on 6 selected samples which had high FOXP3+ Tregs, high B7-H1+ TIL and PD-1+ TIL was performed. The selections were based on sections that had a good morphology to make the interpretation easier. Double-staining assays showed that B7-H1 and FOXP3 molecules were generally expressed by different T lymphocyte subsets (most B7-H1+ TIL were FOXP3- while only very few FOXP3+ Tregs co-express the B7-H1 molecule). In addition, the distribution pattern of B7-H1+ TIL was different from that of FOXP3+ Tregs; Tregs were single cells distributed over the section of the tumor tissues while B7-H1+ TIL aggregated in clumps (Figure 4A). Similarly, PD-1 and FOXP3 molecules were expressed by different T lymphocyte subsets (Figure 4B). Furthermore, double staining assays demonstrated that FOXP3 and CD8 were mainly expressed by two different T lymphocyte subsets (Figure 4C) and only very few CD8+ TIL (< 5%) were FOXP3+. Therefore, it seems that most FOXP3+ Tregs described here are of the CD4+ subset since they were restricted to CD3+ T lymphocytes. On the other hand PD-1 molecule was mainly expressed by CD8+ T lymphocytes with only few CD8- population were positive for PD-1 (Figure 4D). B7-H1 was mainly expressed by CD8- T lymphocytes (Figure 4E) consistent with our previous observation of its expression by CD4+ T lymphocytes [18].
###end p 46
###begin p 47
###xml 0 114 0 114 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Immunohistochemical staining showing the expression of FOXP3, B7-H1 and PD-1 molecules by different subsets of TIL</bold>
###xml 631 632 631 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 637 639 637 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 685 686 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 691 693 691 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 834 835 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 841 843 841 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 888 889 888 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 895 897 895 897 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Immunohistochemical staining showing the expression of FOXP3, B7-H1 and PD-1 molecules by different subsets of TIL. Representative micrographs at x 530 magnification of (A) double staining of B7-H1 (brown color, membranous/cytoplasmic) and FOXP3 (red color, nuclear) in an area rich in TIL of tumor section. (B) Double staining of PD-1 (brown color, membranous) and FOXP3 (red color, nuclear) in sections from the same tumor as in A. (C) double staining of FOXP3 (brown color, nuclear) and CD8 (red color, membranous). (D) double staining of PD-1 (brown color, membranous) and CD8 (red color, membranous). Solid arrows indicate CD8+/PD-1+ T lymphocytes and dashed arrow indicates a CD8-/PD-1+ T lymphocyte. (E) Double staining of B7-H1 (brown color, membranous/cytoplasmic) and CD8 (red color, membranous). Solid arrow indicates a CD8+/B7-H1+ T lymphocyte and dashed arrow indicates a CD8-/B7-H1+ T lymphocyte.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 624 629 624 629 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 744 749 744 749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 790 798 <span type="species:ncbi:9606">patients</span>
The immune system use intricate balance between positive and negative signals to protect the body from foreign agents while preventing autoimmunity [33]. This balance seems to be disturbed in various pathological conditions resulting in either inhibition of the immune system allowing invasion by tumor cells, or stimulation of the immune system to cause autoimmune diseases. For example, although interaction of B7-H1, a coinhibitory molecule, with its PD-1 ligand is important for prevention of autoimmunity [34], tumor cells use this interaction as a mechanism of immune evasion [35]. Furthermore, while the presence of Tregs is important for suppression of host immune response to prevent autoimmune diseases [36], tumor cells can recruit Tregs to inhibit anti-tumor immunity in cancer patients [37].
###end p 49
###begin p 50
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 318 323 318 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 452 461 452 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 650 655 650 655 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 773 778 773 778 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 826 831 826 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 888 890 888 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 891 896 891 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1017 1019 1017 1019 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1020 1025 1020 1025 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1085 1087 1085 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1119 1124 1119 1124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1177 1178 1177 1178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1182 1184 1182 1184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1185 1190 1185 1190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1209 1210 1209 1210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1214 1216 1214 1216 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1259 1264 1259 1264 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1346 1348 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1349 1351 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1399 1404 1399 1404 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1444 1446 1444 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1447 1449 1447 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 717 725 <span type="species:ncbi:9606">patients</span>
###xml 844 849 <span type="species:ncbi:9606">human</span>
###xml 950 958 <span type="species:ncbi:9606">patients</span>
###xml 1434 1442 <span type="species:ncbi:9606">patients</span>
We have shown previously an abundant expression of B7-H1 molecule in high-risk breast cancer patients [18] who have highly proliferative tumor cells [32] and suggested the involvement of this molecule in the progression of the disease. In the present report we expanded our study to investigate the co-involvement of Tregs with B7-H1 in the immune evasion of breast cancer. Although the interaction between the two types of cells has been demonstrated in vitro and animal models, their relative infiltration and correlation with the clinicopathological parameters of cancer patients have not been well studied. In this study, we investigated FOXP3+ Tregs and TIL-expressing B7-H1 and its ligand PD-1 in breast cancer patients. We have used FOXP3 as a detection marker for Tregs as it became recently a biomarker for studying Tregs in malignant human cancers [23]. We have found that FOXP3+ Tregs are abundant in tumor tissues of 56% of breast cancer patients but absent in normal tissues adjacent to the tumors. FOXP3+ Tregs infiltrating tumors have been reported by other studies [25,26,38]. Abundant accumulation of Tregs in tumor tissues might be due to the induction of CD4+CD25+ Tregs from peripheral CD4+CD25- T lymphocytes [39,40] and/or migration of Tregs from other parts of the body to the tumor area by chemotactic factors like CCL22 [24,41]. This hypothesis is supported by increase of Tregs in peripheral blood of cancer patients [25,42].
###end p 50
###begin p 51
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 241 243 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 244 249 244 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 394 396 394 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 443 445 443 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 508 514 508 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 551 556 551 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1069 1071 1066 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1099 1104 1096 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1105 1107 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1134 1136 1131 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1137 1142 1134 1139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1201 1206 1198 1203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1341 1343 1338 1340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1477 1479 1474 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1534 1536 1531 1533 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1537 1542 1534 1539 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1730 1732 1727 1729 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1733 1738 1730 1735 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1749 1751 1746 1748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Standard prognostic factors linked to high-risk breast cancer patients include: young age, large tumor size, high histological grade, positive lymph node metastasis and negative hormonal receptors status [43]. We have demonstrated that FOXP3+ Tregs infiltrating tumor tissues correlates significantly with important bad prognostic factors: large tumor size (P = .029), high histological grade (P < .001) and estrogen receptor negative status (P = .010). Similar findings have been recently reported by Bates et al showing an association between high Tregs numbers, and high histological grade and estrogen receptor negative status [26]. Estrogen receptor negative breast tumors are generally associated with poor prognosis which is usually attributed to the association with high proliferative rate and lack of differentiation [44], that are features of progenitors of stem-like cells. Indeed it has been shown recently that stem cells obtained from both normal and cancer breast tissues lack the estrogen receptor [45]. Such stem cells were found to produce TGFbeta1 [45] which is known to induce Tregs [46]. The association of FOXP3+ Tregs with bad prognostic factors may suggest a contribution of Tregs infiltrating breast cancer tissues to tumor escape from the immune system as their depletion lead to tumor rejection in animal models [47]. We have also confirmed the B7-H1 expression in TIL and its correlation with bad prognostic factors reported in our previous study [18]. The association of B7-H1 expression in TIL and FOXP3+ Tregs infiltration with the same bad prognostic factors suggests that both molecules correlate with each other. Indeed, there was a highly significant correlation between the expression of FOXP3+ Tregs and B7-H1 (P < .0001).
###end p 51
###begin p 52
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 504 505 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 506 507 506 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 543 545 543 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 546 550 546 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 557 559 557 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 571 573 571 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 663 665 663 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 712 714 712 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1025 1027 1025 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1028 1032 1028 1032 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs</sub>
###xml 1039 1041 1039 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1053 1055 1053 1055 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1132 1133 1132 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1210 1215 1210 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1389 1391 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
We have also found that PD-1 expression in TIL correlated with bad prognostic factors. PD-1 has been reported to be expressed in normal tissues to regulate self-reactive T cell responses [48]. In the present study PD-1 was expressed in up to 30% of T lymphocytes from normal breast tissues while up to 80% of TIL were PD-1+. The abundant expression of PD-1 in TIL together with B7-H1 (absent in normal tissues) seen in the present study may contribute to downregulation of the patients' immune response [4,6]. Furthermore, combination of FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL were found to be highly associated with patients who had high histological grade III (P < .001) and estrogen receptor negative tumors (P < .007) suggestive of synergistic contribution to bad prognosis. It seems that FOXP3, B7-H1 and PD-1 molecules co-expressed in the TIL of the same tumor tissues may have synergistic effect in weakening the immune response of patients. IL-2 may play a fundamental role in regulating the interaction between FOXP3+ Tregs, B7-H1+ TIL and PD-1+ TIL. B7-H1/PD-1 interaction contributes to induction of T lymphocyte anergy [4] and this can be restored in the presence of IL-2 [49]. On the other hand, Tregs are dependent on IL-2 for their expansion and function, and consumption of IL-2 present in the microenvironment may increase the inhibitory effect of B7-H1/PD-1 interaction [50].
###end p 52
###begin p 53
###xml 165 170 165 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 204 206 204 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 215 217 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 391 396 391 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 468 470 468 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 520 526 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 623 625 623 625 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 640 642 640 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 788 790 788 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
We also investigated in the present study whether FOXP3, B7-H1 and PD-1 molecules are expressed by different T lymphocyte subsets. We have demonstrated that FOXP3+ Tregs is a separate population from PD-1+ and B7-H1+ TIL. Similar results have been recently reported in non-Hodgkin's lymphoma by Yang et al [41] who showed that PD-1 and B7-H1 expression were mainly found in a subset of non-Tregs T lymphocytes. The expression of FOXP3 was confirmed to be linked to CD4+ T lymphocytes as it has been reported by Roncador et al [51]. We have also confirmed our previous findings showing that B7-H1 was expressed mainly in CD4+ T lymphocytes [18]. On the other hand, we have shown that PD-1 molecules were expressed mainly by CD8+ T lymphocytes. It is important to mention that exhausted CD8+ T lymphocytes have been reported to express the PD-1 molecule and its blockade restored the function of these T lymphocytes [52].
###end p 53
###begin p 54
###xml 273 278 273 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 579 584 579 584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 798 803 798 803 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 899 901 899 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 933 938 933 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1223 1228 1223 1228 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 1318 1320 1318 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 1041 1049 <span type="species:ncbi:9606">patients</span>
###xml 1379 1387 <span type="species:ncbi:9606">patients</span>
One of the most important findings of this study is the co-localization of immunosuppressive molecules expressed by different subsets of T lymphocytes in a group of high-risk breast cancer patients. Indeed, induction of immunosuppressive molecules such as B7-H1, PD-1 and Tregs have been recently shown to counteract the anti-tumor effect of IL-12-based gene therapy in a transgenic mouse model of liver cancer [53]. Therefore, current interests in breast cancer immunotherapy should be focused on designing immunological tools to block B7-H1 and its PD-1 ligand and to deplete Tregs in addition to cancer vaccination [54]. Blocking B7-H1 and PD-1 molecules with monoclonal antibodies or soluble ligands has been shown to enhance cancer immunity in animal models [55]. In addition, elimination of Tregs by an anti-CD25 mAb enhanced anti-tumor immunity and induced tumor regression in animal models [47]. Furthermore, elimination of Tregs by IL-2-conjugated to diphtheria-toxin (ONTAK) enhanced vaccine-mediated anti-tumor immunity in cancer patients [56]. Interestingly, a very recent study, in an animal model of renal cell carcinoma, has shown that only triple treatment consisting of tumor vaccine, B7-H1 blockade, and Tregs depletion can result in a complete tumor regression and long lasting protective immunity [57] supporting the use of triple therapy treatment of cancer patients.
###end p 54
###begin title 55
Conclusion
###end title 55
###begin p 56
###xml 308 313 308 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">regs </sub>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
In conclusion, we have shown a concurrent and abundant infiltration of different immune suppressive subsets of T lymphocytes in the microenvironment of high-risk breast cancer patients. This interesting observation suggests the development of a new therapeutic modalities aiming at targeting B7-H1/PD-1 and Tregs in addition to still-developing immunotherapy.
###end p 56
###begin title 57
Competing interests
###end title 57
###begin p 58
The author(s) declare that they have no competing interests.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
HG designed the study, carried out the immunohistochemistry for B7-H1, coordinated the work and wrote the manuscript. EB carried out immunohistochemistry of PD-1, FOXP3, and CD8 molecules. AT (anatomical pathologist) read and interpreted the sections. NE (statistician) carried out the statistical analysis. TA (medical oncologist) participated in conceiving the study and provided the clinical data. SD (principal investigator) wrote the proposal, conceived, supervised the study, and wrote the manuscript. All authors read and approved the final manuscript.
###end p 60
###begin title 61
Pre-publication history
###end title 61
###begin p 62
The pre-publication history for this paper can be accessed here:
###end p 62
###begin p 63

###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
We are very grateful to the administration of the Research Centre and the Office of Research Affairs (ORA) for their support. This work was sponsored by KFSH&RC (RAC # 2030 034). We would like to thank Drs. Monther Al-Alwan and Ayodele Alaiya for critical review for the manuscript, and Zuha Al-Mukhlafi and Manogaran Pulicat for analyzing the FACS data.
###end p 65
###begin article-title 66
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
###end article-title 66
###begin article-title 67
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
###end article-title 67
###begin article-title 68
Strategies of tumor immune evasion
###end article-title 68
###begin article-title 69
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
###end article-title 69
###begin article-title 70
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
###end article-title 70
###begin article-title 71
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
###end article-title 71
###begin article-title 72
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy
###end article-title 72
###begin article-title 73
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
###end article-title 73
###begin article-title 74
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
###end article-title 74
###begin article-title 75
###xml 111 116 <span type="species:ncbi:9606">human</span>
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
###end article-title 75
###begin article-title 76
###xml 99 104 <span type="species:ncbi:9606">human</span>
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
###end article-title 76
###begin article-title 77
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma
###end article-title 77
###begin article-title 78
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
###end article-title 78
###begin article-title 79
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
###end article-title 79
###begin article-title 80
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis
###end article-title 80
###begin article-title 81
###xml 101 106 <span type="species:ncbi:9606">human</span>
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
###end article-title 81
###begin article-title 82
###xml 93 101 <span type="species:ncbi:9606">patients</span>
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
###end article-title 82
###begin article-title 83
###xml 81 89 <span type="species:ncbi:9606">patients</span>
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors
###end article-title 83
###begin article-title 84
CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production
###end article-title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells
###end article-title 85
###begin article-title 86
Control of regulatory T cell development by the transcription factor Foxp3.[see comment]
###end article-title 86
###begin article-title 87
###xml 57 62 <span type="species:ncbi:9606">human</span>
Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells
###end article-title 87
###begin article-title 88
###xml 68 73 <span type="species:ncbi:9606">Human</span>
The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors
###end article-title 88
###begin article-title 89
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
###end article-title 89
###begin article-title 90
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
###end article-title 90
###begin article-title 91
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
###end article-title 91
###begin article-title 92
Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus
###end article-title 92
###begin article-title 93
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells
###end article-title 93
###begin article-title 94
Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen
###end article-title 94
###begin article-title 95
###xml 33 38 <span type="species:ncbi:9606">human</span>
CD4+CD25high regulatory cells in human peripheral blood
###end article-title 95
###begin article-title 96
Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses
###end article-title 96
###begin article-title 97
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells
###end article-title 97
###begin article-title 98
Developing effective cancer vaccines: design and monitoring are critical
###end article-title 98
###begin article-title 99
Tissue expression of PD-L1 mediates peripheral T cell tolerance
###end article-title 99
###begin article-title 100
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
###end article-title 100
###begin article-title 101
Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells
###end article-title 101
###begin article-title 102
Regulatory T cells in cancer
###end article-title 102
###begin article-title 103
Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast
###end article-title 103
###begin article-title 104
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3
###end article-title 104
###begin article-title 105
###xml 73 78 <span type="species:ncbi:9606">human</span>
De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells
###end article-title 105
###begin article-title 106
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
###end article-title 106
###begin article-title 107
###xml 87 95 <span type="species:ncbi:9606">patients</span>
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
###end article-title 107
###begin article-title 108
###xml 12 20 <span type="species:ncbi:9606">patients</span>
Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor
###end article-title 108
###begin article-title 109
Time-dependence of hazard ratios for prognostic factors in primary breast cancer
###end article-title 109
###begin article-title 110
Molecular definition of breast tumor heterogeneity
###end article-title 110
###begin article-title 111
TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells
###end article-title 111
###begin article-title 112
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody
###end article-title 112
###begin article-title 113
PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues
###end article-title 113
###begin article-title 114
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2
###end article-title 114
###begin article-title 115
###xml 80 88 <span type="species:ncbi:9606">patients</span>
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients
###end article-title 115
###begin article-title 116
###xml 40 45 <span type="species:ncbi:9606">human</span>
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level
###end article-title 116
###begin article-title 117
Restoring function in exhausted CD8 T cells during chronic viral infection
###end article-title 117
###begin article-title 118
###xml 150 155 <span type="species:ncbi:10090">mouse</span>
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer
###end article-title 118
###begin article-title 119
Vaccine immunotherapy in breast cancer treatment: promising, but still early
###end article-title 119
###begin article-title 120
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
###end article-title 120
###begin article-title 121
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
###end article-title 121
###begin article-title 122
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine
###end article-title 122

